# ACE-232

Source: https://onco.cc/drugs/ace-232/  
OnCo record `ace-232` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ACE-232 is an experimental oral small-molecule enzyme inhibitor from Acerand Therapeutics, in phase 1 trials for metastatic castration-resistant prostate cancer.

## Summary

ACE-232 is an oral small-molecule enzyme inhibitor from Acerand Therapeutics. An oral inhibitor of CYP11A1, the enzyme at the first step of steroid hormone production, given with dexamethasone and fludrocortisone. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ACE-232
- Modality: Oral small-molecule enzyme inhibitor
- Mechanism: An oral inhibitor of CYP11A1, the enzyme at the first step of steroid hormone production, given with dexamethasone and fludrocortisone.

## Sources

- Acerand Therapeutics: acerand.com: https://www.acerand.com/news.html
- Acerand Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06801236
- ClinicalTrials.gov: trials of ACE-232: https://clinicaltrials.gov/search?intr=ACE-232

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- targets: [CYP11A1 (cholesterol side-chain cleavage enzyme)](https://onco.cc/targets/cyp11a1/)
- companies: [Acerand Therapeutics](https://onco.cc/companies/acerand-therapeutics/)
- trials: [Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06801236/)

---
JSON: https://onco.cc/api/v1/entities/ace-232.json